

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

The effect of myo-inositol supplementation on nutritional status, cardiometabolic factors, liver function, oxidative stress, visfatin and hs-CRP levels, gene expression of insulin resistance pathway and HIF1 α , NF- κ B, TNF- α , Interleukin-1 β and 6 in patients with non-alcoholic fatty liver disease.

Protocol summary

Study aim

Determining the effect myo-inositol supplementation on nutritional status, cardiometabolic factors, liver function, oxidative stress, visfatin and hs-CRP levels, gene expression of insulin resistance pathway and HIF1 α , NF- κ B, TNF- α , Interleukin-1 β and 6 in patients with non-alcoholic fatty liver disease

Design

Double-blinded placebo-controlled RCT on 50 patients

Settings and conduct

Individuals were randomly allocated into myo-inositol or placebo groups. The duration of the trial will be 8 weeks. At the beginning of the study, both groups will be given nutritional recommendations.

Participants/Inclusion and exclusion criteria

Inclusion criteria: patients with NAFLD (grade 1 and 2) both sexes age 18-55 years BMI between 30-40 kg/m²
exclusion criteria: Athlete, pregnancy, lactation and menopause use of birth control pills and estrogen
Smoking and alcohol use special diet Use of medicines for weight loss Taking medications affecting liver function for 3 months before or during the study
Diseases with similar pathogenesis Intention of getting pregnant

Intervention groups

The intervention group will take myo-inositol supplement (2 gram sachets of myo-inositol before lunch and dinner) and placebo group (2 gram sachets of maltodextrin before lunch and dinner) for 8 weeks. At the beginning of the study, both groups will be given Nutritional recommendations.

Main outcome variables

Nutritional status (energy, macronutrients, micronutrients intake), Cardiometabolic status (glucose-

insulin-HbA1c-HOMA-IR score)- (TG-TC-HDL-C-LDL-C)- SBP,DBP) Oxidative status (GPx , SOD , MDA , CAT, NO, PON1 aryl esterase activity,TAC), visfatin and hs-CRP levels, Expression of inflammatory and insulin resistance genes, anthropometric indices (weight, BMI ,WC, WHR, WHtR)- body composition (Amount and % of body FM, FFM), liver function (liver ultrasonography and enzyme levels of ALT, AST and liver fibrosis score

General information

Reason for update

due to the addition of some variables to the previously approved protocol as well as changes in the title, we request to update this protocol.

Acronym

IRCT registration information

IRCT registration number: **IRCT20100209003320N22**

Registration date: **2021-10-04, 1400/07/12**

Registration timing: **prospective**

Last update: **2023-05-17, 1402/02/27**

Update count: **1**

Registration date

2021-10-04, 1400/07/12

Registrant information

Name

Mehrangiz Ebrahimi mamagani

Name of organization / entity

Health & Nutrition faculty of Tabriz university of medical sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1335 1113

Email address
ebrahimimamagani@tbzmed.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2021-10-23, 1400/08/01

Expected recruitment end date
2022-04-21, 1401/02/01

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
The effect of myo-inositol supplementation on nutritional status, cardiometabolic factors, liver function, oxidative stress, visfatin and hs-CRP levels, gene expression of insulin resistance pathway and HIF1 α , NF-kB, TNF- α , Interleukin-1 β and 6 in patients with non-alcoholic fatty liver disease.

Public title
The effect of myo-inositol supplementation on NAFLD

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Age 18-55 years Body mass index in the range of 30-40 Kg / m² Willingness to cooperate Hepatic steatosis based on Grade 1 and 2 NAFLD disease
Exclusion criteria:
Athlete, pregnancy, lactation and menopause in women Infertility treatment, taking oral contraceptive pills Smoking and alcohol use Adherence to a special diet 3 months before the study Use of chemical or herbal medicines for weight loss and use of hepatotoxic drugs such as phenytoin, amoxicifine , lithium and antihypertensive drugs and lipid-lowering drugs (statins), insulin sensitiser medications Taking antibiotics or dietary supplements that affect the levels of liver enzymes History of weight loss surgery over the last year or rigid weight loss diets three months before the trial Use of corticosteroids and NSAIDs or any type of supplements for 3 months before or during the study Use of any multivitamin (vitamin E and folic acid, etc.), antioxidants (L-arginine, glutamine) and fish oil supplements for 3 months before or during the study those with cardiovascular disease, hepatic, renal, intestinal, thyroid and parathyroid dysfunction, billiary disease, known autoimmune diseases, PCOs, cancers and conditions with mal-absorption such as Sprue and Crohn Having symptoms of a recent infectious, inflammatory disease or recent surgery Candidate or history of Liver transplant Intention for pregnancy

Age
From **18 years** old to **55 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Investigator

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Randomized

Randomization description
A research assistant not otherwise involved in the study, will be randomly allocated 50 patients into one of the two experimental groups (1:1), using the Random allocation software (RAS) and randomized block procedure of size 3 (age (18-30 vs 31-50 years)- gender (female vs male) and BMI (<35 kg/m² vs. \geq 35 kg/m²)).

Blinding (investigator's opinion)
Double blinded

Blinding description
The person in charge of packaging myo-inositol and placebo supplements without knowing the content will determine the type of supplement or placebo that has no role in the implementation and analysis of the study data. None of the researchers or patients will be aware of the type of combination each person is receiving.

Placebo
Used

Assignment
Parallel

Other design features
Patients in both placebo and supplement groups will receive nutritional recommendations .

Secondary Ids
empty

Ethics committees
1

Ethics committee
Name of ethics committee
Ethic Committee of Tabriz University of Medical Sciences
Street address
Golgasht St., Attar Neishaboori Ave., Tabriz University of Medical Sciences, School of Nutrition & Food Sciences
City
Tabriz
Province
East Azarbaijan
Postal code
5166614711

Approval date
2021-09-13, 1400/06/22

Ethics committee reference number
IR.TBZMED.REC.1400.567

Health conditions studied

1

Description of health condition studied

non-alcoholic fatty liver

ICD-10 code

K76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description

Insulin

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

ELISA method

2

Description

HbA1C

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Chromatography

3

Description

Total cholesterol

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Enzymatic-colorimetric method using spectrophotometer

4

Description

Triglyceride

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

enzymatic-colorimetric method using spectrophotometer

5

Description

HDL-C

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Enzymatic-colorimetric method using spectrophotometer

6

Description

LDL-C

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

7

Description

HOMA-IR

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

8

Description

Superoxide dismutase (SOD)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

9

Description

Malondialdehyde (MDA)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

10

Description

Total Antioxidant Capacity (TAC)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

11

Description

Glutathione peroxidase(GPX)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

12

Description

Nitric oxide (NO)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

13

Description

Catalase (CAT)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

14**Description**

paraoxonase arylesterase - 1 (PON-1)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Spectrophotometric method

15**Description**HIF1 α gene expression**Timepoint**

Baseline and 8 weeks after intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

16**Description**

Nuclear factor kappa-B (NF-kB) gene expression

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

17**Description**Tumor necrosis factor alpha (TNF- α) gene expression**Timepoint**

Baseline and 8 weeks after intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

18**Description**

Interleukin-1-beta gene expression

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

19**Description**

Interleukin 6 gene expression

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

20**Description**

Body mass index (BMI)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

21**Description**

Waist circumference

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

measuring tape

22**Description**

waist-to-hip ratio (WHR)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

23**Description**

Waist to Height Ratio (WHtR)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

24**Description**

Fat mass

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Using bioelectric impedance analyzer

25**Description**

Fat Free mass

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Using bioelectric impedance analyzer

26**Description**

Energy, macronutrients and micronutrients intakes

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

a 3-days 24 hour- recall questionnaire at each phase will be completed and analyzed using Nutritionist 4 software

27**Description**

Physical activity level

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Via short form of IPAQ questionnaire

28

Description

Appetite status

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Validated appetite questionnaire

29

Description

Weight

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

using Seca scale

30

Description

Serum albumin

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

using BROMOCRESOL GREEN

31

Description

Platelets count

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Using Coulter counter

32

Description

AMPK gene expression

Timepoint

Baseline and 8 weeks after the intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

33

Description

PDK gene expression

Timepoint

Baseline and 8 weeks after the intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

34

Description

AKT gene expression

Timepoint

Baseline and 8 weeks after the intervention

Method of measurement

Real-time polymerase chain reaction (RT-PCR)

35

Description

Visfatin

Timepoint

Baseline and 8 weeks after the intervention

Method of measurement

ELISA method

36

Description

hs-CRP

Timepoint

Baseline and 8 weeks after the intervention

Method of measurement

ELISA method

Secondary outcomes

1

Description

Fatty liver grade

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Ultrasonigraphy

2

Description

NAFLD fibrosis score

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

3

Description

Alanine aminotransferase (ALT)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

enzymatic method

4

Description

Aspartate aminotransferase (AST)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Enzymatic method

Intervention groups

1

Description

Intervention group: Patients in this group will receive myo-inositol supplement and nutritional recommendation

for 8 weeks. The supplement is: Sachet contains 2 grams of myo-inositol powder dissolved in a glass of water and consumed twice a day 30 minutes before lunch and dinner.

Category

Treatment - Drugs

2**Description**

Control group: Patients in this group will receive placebo and nutritional recommendations for 8 weeks. The placebo is: A sachet containing 2 grams of maltodextrin powder which will be dissolved in a glass of water and consumed twice a day 30 minutes before lunch and dinner.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

School of Nutrition and Food Sciences

Full name of responsible person

Dr. Mehrangiz Ebrahimi-Mameghani

Street address

Golgasht St. - Attar Neyshabouri St. - Tabriz University of Medical Sciences- School of Nutrition and Food Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51666-14711

Phone

+98 41 3335 7580

Email

ebrahimimamagani@tbzmed.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Mohammad Samiei

Street address

Golgasht St., Attar Neishaboori Ave., Tabriz University of Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51666-14711

Phone

+98 41 3335 7582

Email

ebrahimimamagani@tbzmed.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Dr. Mehrangiz Ebrahimimamagani

Position

professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Golgasht street ,Attar neyshaburi street, nutrition faculty

City

Tabriz

Province

East Azarbaijan

Postal code

5185747731

Phone

+98 41 3334 1113

Email

mebrahimimameghani@gmail.com

Web page address

<http://www.nutr.tbzmed.ac.ir/>

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Dr. Mehrangiz Ebrahimimamagani

Position

professor

Latest degree

Ph.D.

arefhosseini.sa@gmail.com

Other areas of specialty/work

Nutrition

Street address

Golgasht street,Attar neyshabari street,Tabriz university of medical science,Nutrition faculty

City

tabriz

Province

East Azarbaijan

Postal code

5185747731

Phone

+98 41 3334 1113

Email

mebrahimimameghani@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Sara Arefhosseini

Position

student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

Faculty of Nutrition and Food Sciences., Attar Neyshaburi St, Golghast St

City

Tabriz

Province

East Azarbaijan

Postal code

5166614711

Phone

+98 41 3335 7582

Email

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Data collected for the primary outcomes will be shared

When the data will become available and for how long

Access starting 12 months after publication

To whom data/document is available

The data will only be available for people working in academic institutions.

Under which criteria data/document could be used

The data of the present study will only be accessible by other researchers , for conducting meta-analysis

From where data/document is obtainable

Ms.Sara Arefhosseini, E-mail

address:arefhosseini.sa@gmail.com, cellphone number:

09354720098 and Somaye Rostami E-mail

address:somyrostammi96@gmail.com, cellphone

number:09142399475

What processes are involved for a request to access data/document

The applicant should provide a brief description of the aims and methods of his Meta-analysis . His request will be assessed and , if agreed, the data will be emailed to the applicant. All these procedures will take no longer than 15 days

Comments